دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 4,800,000 تومان- قیمت ویژه : 2,400,000تومان
پکیج دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
- :
قیمت : 1,500,000 تومان- قیمت ویژه : 750,000تومان
Hemodialysis access in Guatemalan children: a story of global health and the power of philanthropy
doi : 10.1007/s00467-024-06627-8
Volume 40, Issue 4 April 2025
Putting the injury back into AKI: understanding AKI phenotypes and improving risk assessment in cardiac surgery–associated AKI
Monitoring and maintaining quality in the paediatric haemodialysis unit
Extracorporeal pediatric renal replacement therapy: diversifying application beyond kidney failure
Biliary, Renal, Neurological, and Skeletal syndrome in a Chinese boy
Xanthogranulomatous pyelonephritis in a child with autoimmune joint disease
Bone impairment in atypical hemolytic and uremic syndrome treated by long-term eculizumab
“None of us asked to be in this community.� Understanding nephrotic syndrome through TikTok: patient and caregiver perspectives
C3 glomerulopathy in children: a European longitudinal study evaluating outcome
Favorable outcome in children with dense deposit disease with the use of long-term mycophenolate mofetil and high-dose alternate-day steroids
Single (375Â mg/m2) vs. double dose of rituximab along with mycophenolate mofetil for children with steroid-dependent/frequently relapsing nephrotic syndrome: a multicentre open-label randomized controlled trial
Effect of desmopressin on water and solute circadian rhythms in treatment-naïve children with monosymptomatic enuresis and nocturnal polyuria
Fecal microbiome composition in neonates with or without urinary tract infection
Evaluation of predictive performance of fetal urinary inflammatory markers of postnatal kidney function in fetuses with posterior urethral valves
Saline versus balanced crystalloids for hydration post-kidney biopsy
Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody–mediated hemolytic uremic syndrome
Psychological distress in adults after pediatric kidney replacement therapy
Economic burden of inpatient hospitalizations for pediatric chronic kidney disease in the US
Haemolytic uremic syndrome as a cause of chronic kidney disease stage 5 in children is in retreat: results from the Polish Registry of Kidney Replacement Therapy in children (2000–2023)
Use of 4% tetrasodium EDTA (KiteLock™) to prevent central venous catheter–related bloodstream infections in pediatric hemodialysis patients
Balance in children with chronic kidney disease: the relationship between skeletal muscle mass index, fatigue, and physical function
C-C motif chemokine ligand 14 characterization for prediction of persistent severe AKI in post-cardiac surgery children
Kidney and blood pressure outcomes 11Â years after pediatric critical illness and longitudinal impact of AKI: a prospective cohort study
Screening of social determinants of health in pediatric nephrology clinic: a pilot program
Unexplored side effects of eculizumab in adolescents with atypical hemolytic uremic syndrome: the need for further investigation
Eculizumab for pediatric anti-FH antibody-associated atypical hemolytic uremic syndrome: promising results but critical gaps remain
Response to Dr Ahmed and Dr Farooqi:Â Eculizumab versus plasma exchange for pediatric anti-FH antibody-associated atypical hemolytic uremic syndrome
